Bli medlem
Bli medlem

Du är här


Adaptimmune Announces New Additions to Manufacturing Senior Management

tions to Manufacturing Senior Management

PHILADELPHIA and OXFORD, United Kingdom, 2016-01-22 19:17 CET (GLOBE NEWSWIRE)
Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR
engineered T-cell therapy to treat cancer, today announced that it has
augmented its manufacturing leadership to prepare for clinical and commercial
scale up with the additions of William Buecheler as Vice President,
Manufacturing Operations, and Phil Bassett as Head of Process Development.

Mr. Buecheler is responsible for Adaptimmune's global manufacturing operations,
including contract and in-house manufacturing activities, and is leading the
implementation of scale up plans designed to achieve commercial manufacturing
capability. Mr. Bassett is responsible for process development activities
including leading Adaptimmune’s T-cell and lentivirus process development.

“Adaptimmune is in the midst of scaling up its manufacturing expertise, which
significantly enhances our ability to run multiple clinical studies of our TCR
therapies and, eventually, commercialize our products,” said James Noble, Chief
Executive Officer. “As such, manufacturing excellence is key to our long term
success. Hiring the best in the field of manufacturing is critical to us, and
Bill and Phil are already making significant contributions.”

Bill Buecheler brings to Adaptimmune over 25 years of industry experience in
manufacturing operations, facility planning and expansion, leadership of FDA
pre-approval inspection and document preparation, and manufacturing process
improvements. He joins Adaptimmune from Novartis Pharmaceuticals, where he
acted as the Director and Process Unit Head, with responsibility for overall
manufacturing operations of the Cell and Gene Therapy Process Unit. As a member
of the senior leadership team, his responsibilities included manufacturing
efforts to support the scale up operations for Novartis’ CTL019 chimeric
antigen receptor product for treatment of ALL and CLL patients. Prior to
joining Novartis, he worked and consulted for numerous pharmaceutical and
biotech companies in areas including facility build out and expansion, change
control, process improvement, cycle time reduction and critical path project
management. Mr. Buecheler earned his Master of Business Administration degree
from Syracuse University.

Phil Bassett brings with him over 15 years of process manufacturing experience
in CMO, small biotech and large biopharma environments. Most recently, Mr.
Bassett served as Head of Manufacturing Development for the Cell Therapy
Catapult, a UK-based Center of Excellence in cell therapy, where he was
responsible for technology transfer and providing late stage commercial
manufacturing, scale-up and process industrialization expertise. Prior to the
Cell Therapy Catapult, he served at UCB Celltech as the Associate Director and
Head of Fermentation Process Sciences, managing the upstream development team
working on clinical and commercial processes, and leading process development,
scale up and technology transfer efforts. He also spent several years in roles
of increasing responsibility with Cobra Biomanufacturing plc, a UK-based
international contract development and manufacturing organization providing
biologics for pre-clinical and clinical supply.

About Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel
cancer immunotherapy products based on its T-cell receptor (TCR) platform.
Established in 2008, the company aims to utilize the body’s own machinery - the
T-cell - to target and destroy cancer cells by using engineered, increased
affinity TCRs as a means of strengthening natural patient T-cell responses.
Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the
NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has
demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid
tumors and in hematologic cancer types, including synovial sarcoma and multiple
myeloma. In June 2014, Adaptimmune announced that it had entered into a
strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for
the development and commercialization of the NY-ESO TCR program in partnership
with GSK. In addition, Adaptimmune has a number of proprietary programs. The
company has identified over 30 intracellular target peptides preferentially
expressed in cancer cells and is currently progressing 12 through unpartnered
research programs. Adaptimmune has over 200 employees and is located in
Oxfordshire, U.K. and Philadelphia, USA. For more information:

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking
statements involve certain risks and uncertainties. Such risks and
uncertainties could cause our actual results to differ materially from those
indicated by such forward-looking statements, and include, without limitation:
the success, cost and timing of our product development activities and clinical
trials and our ability to successfully advance our TCR therapeutic candidates
through the regulatory and commercialization processes. For a further
description of the risks and uncertainties that could cause our actual results
to differ materially from those expressed in these forward-looking statements,
as well as risks relating to our business in general, we refer you to our
Annual Report on Form 20-F filed with the Securities and Exchange Commission on
October 13, 2015. The forward-looking statements contained in this press
release speak only as of the date the statements were made and we do not
undertake any obligation to update such forward-looking statements to reflect
subsequent events or circumstances.

Adaptimmune Contacts

Will Roberts
Vice President, Investor Relations
T: (215) 825-9306

Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mob: +44 (0)7710 304249

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.